SPIRONOLACTONE THERAPY FOR CARDIOMYOPATHY IN DUCHENNE MUSCULAR DYSTROPHY

Michelle Ploutz,Ryan A. Moore,Masatoshi Ashiki, Bethany Wisotzkey,BreAnn Taylor,Christopher Spurney,Michael D. Taylor,John L. Jefferies

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2017）

引用 0|浏览4

暂无评分

摘要

Background: Cardiomyopathy is a leading cause of death in Duchenne muscular dystrophy (DMD). Eplerenone can prevent progressive left ventricular (LV) dysfunction when added to baseline therapies; however, it is not readily available and has a higher cost point. We, therefore, tested the hypothesis

查看译文

关键词

spironolactone therapy,cardiomyopathy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要